Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00499902 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
A Phase 2 study, sponsored by ARCA Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00499902 is a Phase 2 study that was terminated before completion, run by ARCA Biopharma. The registered enrollment target is 7 participants.
The verdict
NCT00499902, a Phase 2 study, was terminated before completion, sponsored by ARCA Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
Interventions
- DRUG alfimeprase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00499902
The ClinicalTrials.gov registry entry for NCT00499902 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alfimeprase is the first listed.
NCT00499902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00499902 about?
NCT00499902 is a clinical study titled "Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke". The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
What is the current status of trial NCT00499902?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-06. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00499902?
The interventions under investigation include: alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00499902?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.